For Doctors in a Hurry
- Researchers investigated if 2C-B produces psychoactive effects comparable to MDMA or psilocybin for potential use in psychiatric treatment.
- This randomized, placebo-controlled, crossover study evaluated 24 healthy participants receiving 2C-B, 125 mg MDMA, or 25 mg psilocybin.
- The 30 mg 2C-B dose increased emotional empathy similarly to MDMA, with a 4.9-hour duration and lower cardiovascular stimulation.
- The researchers concluded that 30 mg of 2C-B induces entactogenic and psychedelic effects with less distress than psilocybin.
- These findings establish dose-proportional pharmacokinetics and safety profiles to guide future clinical trials for posttraumatic stress and depression.
Expanding the Pharmacopoeia of Psychedelic-Assisted Therapy
The resurgence of interest in psychedelic-assisted therapy has primarily focused on psilocybin and 3,4-methylenedioxymethamphetamine (MDMA) for treating treatment-resistant depression and posttraumatic stress disorder [1, 2]. While these compounds show efficacy in modulating neural networks and promoting neuroplasticity (the brain's ability to reorganize itself by forming new neural connections), their clinical utility is often constrained by long durations of action and significant autonomic stimulation [3, 4]. Clinicians are increasingly evaluating a broader range of phenethylamines (a class of compounds with stimulant and hallucinogenic properties) to identify molecules with improved safety or logistical profiles [5, 6, 7]. Among these, 4-bromo-2,5-dimethoxyphenethylamine (2C-B) has gained attention as a substance that may bridge the gap between the empathogenic (emotion-enhancing) effects of MDMA and the hallucinogenic properties of classic psychedelics [8, 9]. A new double-blind, placebo-controlled study comparing 30 mg of 2C-B, 125 mg of MDMA, and 25 mg of psilocybin now provides a rigorous comparison to clarify the potential role of 2C-B in the clinical setting [10].
A Head-to-Head Comparison of Three Psychoactive Classes
To evaluate the clinical profile of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) against established therapeutic benchmarks, researchers conducted a double-blind, randomized, placebo-controlled, crossover study. This specific design, where each participant serves as their own control by receiving every treatment in a random sequence, included 24 healthy participants consisting of 12 women and 12 men. The trial compared the acute effects of three escalating doses of 2C-B (10 mg, 20 mg, and 30 mg) against a standard therapeutic dose of 125 mg of MDMA and a high dose of 25 mg of psilocybin. By utilizing this head-to-head framework, the study aimed to delineate how 2C-B differs from the empathogenic effects of MDMA and the profound alterations in consciousness typically induced by psilocybin.
The investigation employed a comprehensive battery of outcome measures to capture both the psychological and physiological impact of these substances over a 9-hour period. Beyond assessing acute subjective effects (the patient's self-reported experience) and adverse effects, the researchers monitored autonomic effects, such as changes in heart rate and blood pressure. To quantify the social and emotional impact of the drugs, the study measured emotional and cognitive empathy, which distinguishes between the ability to feel what another person feels and the intellectual understanding of another's perspective. Furthermore, the team tracked objective biomarkers by measuring plasma oxytocin and neurophysin I concentrations (hormones and carrier proteins associated with social bonding and emotional regulation) and established the pharmacokinetics (how the body absorbs, distributes, and eliminates the drug) for each substance to determine their respective durations of action.
Dose-Dependent Subjective Profiles and Emotional Empathy
The study demonstrated that 2C-B produced dose-dependent subjective effects across the 10 mg, 20 mg, and 30 mg cohorts, allowing for a clear characterization of its pharmacodynamic profile (the relationship between drug concentration and its effect on the body). When assessing the overall intensity of the experience, the researchers found that the 30 mg dose of 2C-B exerted comparable "any drug effects" to 125 mg of MDMA. This suggests that at this specific dosage, 2C-B reaches a level of subjective potency that clinicians might associate with a standard therapeutic dose of MDMA. However, the data also indicated that the 30 mg dose of 2C-B exerted lower "any drug effects" than 25 mg of psilocybin, positioning it as a less intense experience than high-dose psilocybin sessions.
Qualitatively, the 30 mg dose of 2C-B appears to bridge the gap between traditional psychedelics and empathogens. The researchers observed that the 30 mg dose of 2C-B induced psychedelic-type alterations of state of consciousness, which involve changes in sensory perception and cognitive processing similar to those produced by psilocybin. Concurrently, the 30 mg dose of 2C-B increased emotional empathy similarly to 125 mg of MDMA, specifically enhancing the ability to share another person's emotional state. This dual action confirms that the 30 mg dose of 2C-B induces entactogenic (empathy-enhancing and socially connecting) and psychedelic effects similarly to MDMA and psilocybin, respectively. For the practicing clinician, this hybrid profile suggests that 2C-B may facilitate both the emotional openness required for trauma processing and the perceptual shifts utilized in treating depressive disorders.
Clinical Logistics: Duration and Tolerability
From a clinical management perspective, the temporal profile of a psychoactive compound determines the necessary duration of supervised monitoring and the overall throughput of a specialized clinic. The researchers found that the average subjective effect duration of 30 mg 2C-B was 4.9 hours, a timeframe that closely aligns with the 4.8-hour subjective effect duration of 125 mg MDMA. In contrast, the subjective effect duration of 25 mg psilocybin was 6.1 hours, representing a significantly longer commitment for both the patient and the clinical staff. This shorter five-hour window for 2C-B may offer a logistical advantage in outpatient settings, potentially allowing for more flexible scheduling compared to the extended sessions required for high-dose psilocybin administration.
The psychological tolerability of these substances is equally critical for patient safety and the prevention of adverse events during therapy. The study data revealed that only 25 mg psilocybin induced "bad drug effects" and "anxiety" compared with placebo, whereas 2C-B and MDMA did not produce these distressing responses at the doses tested. Specifically, the authors concluded that at the tested dose-level, psilocybin is more distressing than MDMA and 2C-B. For clinicians, these findings suggest that 30 mg of 2C-B provides a more manageable psychological profile than 25 mg of psilocybin, characterized by a lower risk of acute anxiety and negative subjective experiences while maintaining the desired therapeutic duration.
Autonomic Safety and Pharmacokinetic Properties
The cardiovascular safety profile of psychoactive compounds is a primary concern for clinicians, particularly when treating patients with underlying autonomic sensitivities. In this crossover trial, the researchers observed that MDMA produced the highest cardiovascular stimulation, followed by psilocybin and then 2C-B. This finding indicates that 2C-B is less cardiostimulant than MDMA and psilocybin, suggesting a lower burden on heart rate and blood pressure at the doses evaluated. While MDMA is known for its robust sympathomimetic activity (the stimulation of the sympathetic nervous system that increases heart rate and blood pressure), 2C-B appears to offer a more attenuated autonomic response. This favorable cardiac profile may broaden the potential patient population eligible for treatment in a supervised clinical setting.
The study also identified distinct differences in the biochemical markers associated with these substances. Although 2C-B and MDMA produced similar subjective effects on emotional empathy, their underlying mechanisms appear to diverge. The researchers found that only MDMA increased plasma oxytocin and neurophysin I concentrations, which are hormones and carrier proteins associated with social bonding and water balance. The absence of an increase in these markers following 2C-B administration suggests that its empathogenic properties may be mediated through pathways independent of the oxytocin system, unlike the prototypical response seen with MDMA.
From a metabolic perspective, the researchers found that 2C-B exhibited dose-proportional pharmacokinetics, meaning that the plasma concentration of the drug increased in direct proportion to the administered dose of 10, 20, or 30 mg. This predictability is essential for clinical dose-finding and safety monitoring. Furthermore, the data showed that 2C-B had a plasma elimination half-life of approximately 1.3 hours. This rapid clearance supports the shorter clinical duration of the drug and provides a manageable pharmacokinetic window for outpatient administration, allowing for a predictable return to baseline physiological states.
References
1. Gondi CS, Gnanamony M, Gondi TP, Nersesyan L, Demirkhanyan L. Psychedelics and Autism Therapy: A Review of Current Research and Future Directions. Current Issues in Molecular Biology. 2026. doi:10.3390/cimb48040417
2. Hoyer D. Psychedelics, entactogens and psychoplastogens for depression and related disorders. British Journal of Pharmacology. 2025. doi:10.1111/bph.70088
3. Ley L, Holze F, Arikci D, et al. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Neuropsychopharmacology. 2023. doi:10.1038/s41386-023-01607-2
4. Holze F, Ley L, Müller F, et al. Direct comparison of the acute effects of lysergic acid diethylamide and psilocybin in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology. 2022. doi:10.1038/s41386-022-01297-2
5. Pulido-Saavedra A, Oliva HNP, Prudente TP, et al. Effects of psychedelics on opioid use disorder: a scoping review of preclinical studies. Cellular and Molecular Life Sciences. 2025. doi:10.1007/s00018-024-05519-2
6. Egger K, Aicher H, Cumming P, Scheidegger M. Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors. Cellular and Molecular Life Sciences. 2024. doi:10.1007/s00018-024-05353-6
7. Inan F, Brunt TM, Contrucci RR, Hondebrink L, Franssen EJF. Novel Phenethylamines and Their Potential Interactions With Prescription Drugs: A Systematic Critical Review. Therapeutic Drug Monitoring. 2020. doi:10.1097/ftd.0000000000000725
8. Mallaroni P, Mason NL, Reckweg JT, et al. Assessment of the Acute Effects of 2C‐B vs. Psilocybin on Subjective Experience, Mood, and Cognition. Clinical Pharmacology & Therapeutics. 2023. doi:10.1002/cpt.2958
9. Nasr M, Assadi B, Weissman BC, Gleason O, Seikunas J, Puthiyathu M. Emerging Illicit Drug “2C”: A Case Report on Its Hallucinogenic and Stimulant Properties. Cureus. 2024. doi:10.7759/cureus.69407
10. Arikci D, Borgulya J, Straumann I, et al. Acute dose-dependent effects of 4-bromo-2,5-dimethoxyphenethylamine (2C-B) compared with 3,4-methylenedioxymethamphetamine (MDMA) and psilocybin in a double-blind, placebo-controlled study in healthy participants.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2026. doi:10.1038/s41386-026-02428-9
